Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    NCT01478373
Show Display Options
Rank Status Study
1 Completed Efficacy and Safety of Dovitinib in Patients With Gastrointestinal Stromal Tumors Refractory and/or Intolerant to Imatinib
Condition: Gastrointestinal Stromal Tumors
Intervention: Drug: Dovitinib (TKI258)

Indicates status has not been verified in more than two years